Unum Therapeutics Inc (UMRX) Stock Price, Quote, News and Overview
NASDAQ:UMRX - Nasdaq -
UMRX Quote, Performance and Key Statistics
NASDAQ:UMRX (10/5/2020, 8:00:05 PM)
2.35
+0.01 (+0.43%)
The current stock price of UMRX is 2.35 null. In the past month the price increased by 6.82%. In the past year, price increased by 67.86%.
About UMRX
Company Profile
Unum Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel immunotherapy products of immune system to cure cancer. The company's program consists of ACTR087 rituximab, ACTR707 RITUXIMAB, ACTR087 SEA-BCMA which are in clinical stage. Unum Therapeutics Inc. is based in Cambridge, United States.
Company Info
Unum Therapeutics Inc
200 CAMBRIDGE PARK DRIVE SUITE 3100
CAMBRIDGE MA 02140
CEO: Charles Wilson
Phone: 617-945-5576
Unum Therapeutics Inc / UMRX FAQ
What is the stock price of Unum Therapeutics Inc today?
The current stock price of UMRX is 2.35 null. The price increased by 0.43% in the last trading session.
What is the ticker symbol for Unum Therapeutics Inc stock?
The exchange symbol of Unum Therapeutics Inc is UMRX and it is listed on the Nasdaq exchange.
On which exchange is UMRX stock listed?
UMRX stock is listed on the Nasdaq exchange.
What is Unum Therapeutics Inc worth?
Unum Therapeutics Inc (UMRX) has a market capitalization of 99.80M null. This makes UMRX a Micro Cap stock.
What are the support and resistance levels for Unum Therapeutics Inc (UMRX) stock?
Unum Therapeutics Inc (UMRX) has a support level at 2.3 and a resistance level at 2.36. Check the full technical report for a detailed analysis of UMRX support and resistance levels.
Should I buy Unum Therapeutics Inc (UMRX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of UMRX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of UMRX, evaluating the profitability, health, valuation and growth aspects
- Unum Therapeutics Inc (UMRX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Unum Therapeutics Inc (UMRX) Sales and EPS estimates to see what analysts future expectations are.
- Unum Therapeutics Inc (UMRX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Unum Therapeutics Inc (UMRX) Insider and Institutional Ownership to learn about the owners and their transactions.
- Unum Therapeutics Inc (UMRX) Stock Chart to make your own analysis
- Unum Therapeutics Inc (UMRX) Latest news and press-releases to stay up to date.
Does Unum Therapeutics Inc (UMRX) stock pay dividends?
UMRX does not pay a dividend.
What is the Price/Earnings (PE) ratio of Unum Therapeutics Inc (UMRX)?
Unum Therapeutics Inc (UMRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.76).
UMRX Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to UMRX. When comparing the yearly performance of all stocks, UMRX is one of the better performing stocks in the market, outperforming 79.87% of all stocks.
UMRX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to UMRX. UMRX has a bad profitability rating. Also its financial health evaluation is rather negative.
UMRX Financial Highlights
Over the last trailing twelve months UMRX reported a non-GAAP Earnings per Share(EPS) of -0.76. The EPS increased by 44.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -96.84% | ||
| ROA | -74.43% | ||
| ROE | N/A | ||
| Debt/Equity | 0.18 |
UMRX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to UMRX. The Buy consensus is the average rating of analysts ratings from 3 analysts.